Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report

Infections in critically-ill patients caused by extensively-drug-resistant (XDR)-Pseudomonas aeruginosa are challenging to manage due to paucity of effective treatment options. Cefepime/zidebactam, which is currently in global Phase 3 clinical development (Clinical Trials Identifier: NCT04979806, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubey, Dilip, Roy, Manish, Shah, Tajamul H., Bano, Noor, Kulshrestha, Vidushi, Mitra, Sandeep, Sangwan, Pushpender, Dubey, Madhulika, Imran, Ali, Jain, Bhawna, Velmurugan, Aravind, Bakthavatchalam, Yamuna Devi, Veeraraghavan, Balaji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324185/
https://www.ncbi.nlm.nih.gov/pubmed/37408075
http://dx.doi.org/10.1186/s12941-023-00606-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324185/
https://www.ncbi.nlm.nih.gov/pubmed/37408075
http://dx.doi.org/10.1186/s12941-023-00606-x

Ejemplares similares